Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® ...

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® ...

58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety profile consistent with previous studies, with no new safety…

Arcutis reports positive topline data in Zoryve trial for infant AD

Arcutis has reported positive topline data from the INTEGUMENT-INFANT Phase II trialassessing Zoryve cream 0.05% in infants aged three months to below 24 months with mild to moderate AD.The post Arcutis reports positive topline data in Zoryve trial for infant AD appeared first on Clinical Trials Arena.

Will Positive Infant Phase 2 ZORYVE Data Expand Arcutis Biotherapeutics' (ARQT) Atopic Dermatitis Narrative?

Arcutis Biotherapeutics recently reported positive topline results from its INTEGUMENT-INFANT Phase 2 study, showing that once-daily ZORYVE cream 0.05% was well tolerated and improved atopic dermatitis in infants aged 3 months to under 24 months, with low rates of mostly mild to moderate adverse events. The findings extend ZORYVE’s safety and efficacy profile into even younger pediatric patients, potentially broadening its role as a non-steroida…

Phase 2 Data Highlight Roflumilast Cream in Infant AD

Arcutis reveals promising phase 2 results for roflumilast cream in infants with AD, highlighting safety and potential efficacy.

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis

Open the article to view the coverage from Arcutis Biotherapeutics